282 related articles for article (PubMed ID: 24788563)
1. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
[TBL] [Abstract][Full Text] [Related]
3. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).
Dorff TB; Quinn DI; Pinski JK; Goldkorn A; Sadeghi S; Tsao-Wei D; Groshen S; Kuhn P; Gross ME
Clin Genitourin Cancer; 2019 Aug; 17(4):241-247.e1. PubMed ID: 31227432
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Araujo JC; Mathew P; Armstrong AJ; Braud EL; Posadas E; Lonberg M; Gallick GE; Trudel GC; Paliwal P; Agrawal S; Logothetis CJ
Cancer; 2012 Jan; 118(1):63-71. PubMed ID: 21976132
[TBL] [Abstract][Full Text] [Related]
6. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Yu EY; Massard C; Gross ME; Carducci MA; Culine S; Hudes G; Posadas EM; Sternberg CN; Wilding G; Trudel GC; Paliwal P; Fizazi K
Urology; 2011 May; 77(5):1166-71. PubMed ID: 21539969
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN
Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934
[TBL] [Abstract][Full Text] [Related]
8. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
van Dodewaard-de Jong JM; de Klerk JMH; Bloemendal HJ; Oprea-Lager DE; Hoekstra OS; van den Berg HP; Los M; Beeker A; Jonker MA; O'Sullivan JM; Verheul HMW; van den Eertwegh AJM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1319-1327. PubMed ID: 28421240
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Haura EB; Tanvetyanon T; Chiappori A; Williams C; Simon G; Antonia S; Gray J; Litschauer S; Tetteh L; Neuger A; Song L; Rawal B; Schell MJ; Bepler G
J Clin Oncol; 2010 Mar; 28(8):1387-94. PubMed ID: 20142592
[TBL] [Abstract][Full Text] [Related]
10. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Lara PN; Ely B; Quinn DI; Mack PC; Tangen C; Gertz E; Twardowski PW; Goldkorn A; Hussain M; Vogelzang NJ; Thompson IM; Van Loan MD
J Natl Cancer Inst; 2014 Apr; 106(4):dju013. PubMed ID: 24565955
[TBL] [Abstract][Full Text] [Related]
11. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Azad AA; Beardsley EK; Hotte SJ; Ellard SL; Klotz L; Chin J; Kollmannsberger C; Mukherjee SD; Chi KN
Invest New Drugs; 2014 Aug; 32(4):746-52. PubMed ID: 24671507
[TBL] [Abstract][Full Text] [Related]
13. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Koreckij T; Nguyen H; Brown LG; Yu EY; Vessella RL; Corey E
Br J Cancer; 2009 Jul; 101(2):263-8. PubMed ID: 19603032
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
Fizazi K; Ulys A; Sengeløv L; Moe M; Ladoire S; Thiery-Vuillemin A; Flechon A; Guida A; Bellmunt J; Climent MA; Chowdhury S; Dumez H; Matouskova M; Penel N; Liutkauskiene S; Stachurski L; Sternberg CN; Baton F; Germann N; Daugaard G
Ann Oncol; 2017 Nov; 28(11):2741-2746. PubMed ID: 29059273
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Twardowski PW; Beumer JH; Chen CS; Kraft AS; Chatta GS; Mitsuhashi M; Ye W; Christner SM; Lilly MB
Anticancer Drugs; 2013 Aug; 24(7):743-53. PubMed ID: 23652277
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Choi YJ; Kim HS; Park SH; Kim BS; Kim KH; Lee HJ; Song HS; Shin DY; Lee HY; Kim HG; Lee KH; Lee JL; Park KH
Cancer Res Treat; 2018 Oct; 50(4):1252-1259. PubMed ID: 29334610
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
de Bono JS; Piulats JM; Pandha HS; Petrylak DP; Saad F; Aparicio LM; Sandhu SK; Fong P; Gillessen S; Hudes GR; Wang T; Scranton J; Pollak MN
Clin Cancer Res; 2014 Apr; 20(7):1925-34. PubMed ID: 24536060
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
Emmenegger U; Booth CM; Berry S; Sridhar SS; Winquist E; Bandali N; Chow A; Lee C; Xu P; Man S; Kerbel RS; Ko YJ
Oncologist; 2015 Dec; 20(12):1351-2. PubMed ID: 26542984
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]